Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL921288 | 0.98 | EGFR (0.53) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| Nitrous Acid SCHEMBL27969683 | 0.94 | EGFR (0.50) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL921287 | 0.83 | EGFR (0.54) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL846877 | 0.83 | EGFR (0.50) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL8688700 | 0.82 | KEAP1 (0.43) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| SCHEMBL5190356 | 0.82 | POLB (0.52) | EGFRSMN1; SMN2ALDH1A1MAPK1KDM4E | |
| SCHEMBL13983033 | 0.81 | EGFR (0.47) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY | |
| Hydrochloric Acid SCHEMBL5013614 | 0.80 | PARP1 (0.50) | EGFRSMN1; SMN2ALDH1A1MAPK1KDM4E | |
| SCHEMBL8193882 | 0.80 | EGFR (0.58) | EGFRALDH1A1DHODHKEAP1NFE2L2 | |
| SCHEMBL5425587 | 0.79 | EGFR (0.47) | EGFRSMN1; SMN2ALDH1A1MAPK1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 853 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-113880762-B | Triacylamine derivatives containing 1,8-naphthalimide as well as preparation method and application thereof | 河北农业大学 | 2023-02-21 | — | — | CN | claimed |
| CN-113880762-A | 1, 8-naphthalimide-containing triacylamine derivatives, and preparation method and application thereof | 河北农业大学 | 2022-01-04 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| CN-101812016-B | Method for preparing 6-methylnicotinic acid etoricoxib intermediate and ester thereof | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| CN-1694880-A | 6-methylpyridine derivatives, process for preparing the same and antiviral pharmaceutical composition comprising the same | B & C BIOPHARM CO LTD (KR) | 2005-11-09 | — | — | CN | claimed |
| EP-1549642-A1 | 6-METHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C Biopharm Co., Ltd. (KR) | 2005-07-06 | — | — | EP | claimed |
| WO-2004033450-A1 | 6-METHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM CO., LTD. (KR) | 2004-04-22 | — | — | WO | claimed |
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | claimed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | claimed |
| WO-2001078648-A2 | 6-METHYLNICOTINAMIDE DERIVATIVES AS ANTIVIRAL AGENTS | DONG WHA PHARM. IND. CO., LTD. (KR) | 2001-10-25 | — | — | WO | claimed |
| WO-2001055109-A1 | AROMATIC AMIDES ACTING ON MELANOCORTIN RECEPTORS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | EGFR 2133/4885SMN1; SMN2 4271/4885ALDH1A1 3087/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | EGFR 2133/4885SMN1; SMN2 4271/4885ALDH1A1 3087/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | EGFR 2133/4885SMN1; SMN2 4271/4885ALDH1A1 3087/4885 |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | TPMT, HAVCR2, NNMT | EGFR 2627/4885SMN1; SMN2 1842/4885ALDH1A1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.